Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Efficacy and Safety of ABX464 as Maintenance Therapy in Ulcerative Colitis
NCT05535946Phase 3Active, not recruiting
- Sponsor
- Abivax
- Start
- Jan 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of obefazimod in ulcerative colitis (UC), sponsored by Abivax. Started Jan 2023; status: active, not recruiting.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05535946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535946.